Drug Discovery World

FEBRUARY 3, 2023

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

MARCH 23, 2021

AstraZeneca has been rebuked by a US health authority after a trial monitoring board said data published from a large study of its COVID-19 vaccine may be out of date and may not give a representative view of its efficacy. AstraZeneca is preparing to file this and other trial data with the FDA asking for an emergency approval of the vaccine.

Vaccination 98

Vaccination Vaccine Trials Allergies 98

Scienmag

SEPTEMBER 30, 2020

Credit: Stefan Zimmerman Women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age. That is according to a large study by researchers at Karolinska Institutet in Sweden published in New England Journal of Medicine.

Vaccination 97

Vaccination Vaccine Medicine Development 97

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

Scienmag

OCTOBER 5, 2020

Michael Houghton discovered hepatitis C virus and now is developing a vaccine Credit: Photo: Michael Holly Michael Houghton was awarded the 2020 Nobel Prize in Physiology or Medicine today in recognition of his discovery of the hepatitis C (HCV) virus.

Medicine 86

Medicine Vaccination Vaccine Development 86

XTalks

SEPTEMBER 8, 2020

Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

Scienmag

NOVEMBER 4, 2020

The finding provides a surrogate for testing the effectiveness of vaccine candidates Credit: Jennifer Jenks, Duke University School of Medicine DURHAM, N.C.

Vaccination 63

Vaccination Vaccine Research Development 63

XTalks

DECEMBER 7, 2020

Past Few Weeks Herald Good News on the Vaccine Front. First came the news from Pfizer and its German partner BioNTech that their mRNA vaccine was 90 percent effective in preventing symptomatic COVID-19 disease. In their trial, some 30,000 patients received either two doses of Moderna’s mRNA-1273 vaccine 28 days apart or placebo.

Vaccination 52

Vaccination Vaccine Development Drugs 52

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

Scienmag

JANUARY 11, 2021

Scientists reach new milestone in vaccine development for neglected tropical disease Researchers have taken an important step forward in developing a controlled human infection model to test leishmaniasis vaccines.

Scientist 40

Scientist Vaccination Vaccine Development 40

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

Scienmag

SEPTEMBER 3, 2020

A team at the George Washington University Vaccine Research Unit has developed a controlled human hookworm infection model, accelerating the development of human hookworm vaccines WASHINGTON (August 26, 2020) – A team led by researchers at the George Washington University (GW) has established a controlled human hookworm infection (CHHI) model (..)

Vaccination 68

Vaccination Vaccine Research Development 68

Scienmag

NOVEMBER 9, 2020

— Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS […]. UNIVERSITY PARK, Pa.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

Pharmaceutical Technology

AUGUST 5, 2022

The development of therapeutics for transmissible spongiform encephalopathies (TSEs) continues to be challenged by the complex nature of these diseases. It is ultra-rare,” says Jesús Rodriguez Requena, PhD, associate professor in the Department of Medicine at the University of Santiago de Compostela.

Drugs 299

Drugs Protein Vaccination Vaccine 299

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

OCTOBER 29, 2021

Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine authority, Zabdeno ® (Ad26.ZEBOV) These data add to the growing body of substantiation supporting the precautionary use of the Johnson & Johnson Ebola vaccine authority to cover people at threat of Ebola.

Immune Response 40

Immune Response Medicine Vaccination Vaccine 40

Pfizer

JULY 8, 2022

FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. The vaccine was previously made available to this age group in the U.S. Fri, 07/08/2022 - 11:48. Pfizer and BioNTech Announce U.S.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

Drug Discovery World

JANUARY 24, 2024

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. All monkeys that received a placebo infusion acquired SHIV following the challenge. Among monkeys that received VRC34.01

Antibody 52

Antibody Vaccination Vaccine Allergies 52

The Pharma Data

AUGUST 24, 2020

The top US virus expert has warned against rushing out a Covid-19 vaccine before it has been proven to be safe and effective. Speaking to Reuters news agency, Dr Anthony Fauci also said doing so could hurt the development of other vaccines. Oxford coronavirus vaccine triggers immune response.

Vaccination 52

Vaccination Vaccine Immune Response Allergies 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pfizer

DECEMBER 8, 2022

FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza. INDICATION & AUTHORIZED USE Pfizer-BioNTech COVID-19 Vaccine, Bivalent, (Original and Omicron BA.4/BA.5) AUTHORIZED USE .

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Scienmag

JANUARY 8, 2021

Kim focused on developing vaccines for HIV, Ebola and pandemic influenza. But, within days of closing their campus lab space as part of COVID-19 precautions, they turned their attention to a vaccine for SARS-CoV-2, the virus that causes COVID-19. Although the […].

Vaccination 57

Vaccination Vaccine Development Allergies 57

The Pharma Data

MARCH 2, 2021

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. “For

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 9, 2023

After a long period without any new approvals, in May, the FDA approved GSK’s vaccine Arexvy for the prevention of LRTD caused by RSV in individuals 60 and older. On 31 May, the FDA also approved Pfizer’s vaccine Abrysvo in the same patient population. The European Commission approved nirsevimab in November 2022.

FDA Approval 147

FDA Approval Antibody Allergies Packaging 147

The Pharma Data

JULY 12, 2021

Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. For further information on the safety of authorized COVID-19 vaccines, please visit: [link]. What Is the Janssen COVID-19 Vaccine?

Vaccination 52

Vaccination Vaccine FDA Approval Allergies 52

Pfizer

JULY 8, 2022

Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®. Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®. Pfizer-BioNTech COVID-19 Vaccine is FDA authorized to provide: Primary Series.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

Drug Discovery World

DECEMBER 13, 2023

She will be followed by Andrea Bortolato, Director of Drug Discovery at SandboxAQ, at 3pm, who will speak on ‘Combining physics-based methods with AI solutions to maximise the probability of success and speed of drug discovery and development’. Register now to show your interest.

Allergies 52

Allergies Engineer Drugs Development 52

Scienmag

MARCH 24, 2021

Governments should prioritise surgical patients for COVID-19 vaccination Patients waiting for elective surgery should get COVID-19 vaccines ahead of the general population – potentially helping to avoid thousands of post-operative deaths linked to the virus, according to a new study funded by the NIHR. Between 0.6%

Vaccination 71

Vaccination Vaccine Development Allergies 71

Drug Discovery World

JANUARY 21, 2024

Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population. His recent research focuses on vaccines against influenza and other (re)emerging viruses.

Protein 52

Protein Vaccination Vaccine Development 52

Scienmag

MARCH 2, 2021

New Cleveland Clinic-led research published in mBio Credit: Cleveland Clinic CLEVELAND – Researchers from Cleveland Clinic’s Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.

Vaccination 59

Vaccination Vaccine Research Development 59

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

Scienmag

APRIL 10, 2021

[link] New York, NY (April 10, 2021) – A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase (..)

Vaccination 67

Vaccination Vaccine Development Clinical Trials 67

Drug Discovery World

MARCH 23, 2023

The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. The Pfizer-BioNTech vaccine uses parts of the SARS-CoV-2 spike protein to elicit an immune response without causing infection.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52